The research team began developing a workaround by creating a fusion protein based on the complex formed by BTLA and HVEM. The increased stability from combining these proteins allowed the group ...

The research team began developing a workaround by creating a fusion protein based on the complex formed by BTLA and HVEM. The increased stability from combining these proteins allowed the group ...

The mitochondrial protein that controls calcium transport could be a promising target for Alzheimer's and heart disease drugs ...

The research team began developing a workaround by creating a fusion protein based on the complex formed by BTLA and HVEM. The increased stability from combining these proteins allowed the group ...

Calcium transport into and out of mitochondria -- the powerhouses of cells -- is central to cellular energy production and cell death. To maintain the balance of calcium within these powerhouses, ...

Led by postdoctoral fellow Joanne F. Garbincius, Ph.D., Dr. Elrod's team generated a fusion of NCLX and a biotinylation protein. The fusion protein was then placed back into cells, and other ...

Title : Hemodynamic effects of TX45 , a long-acting Fc-relaxin fusion, in Group 2 pulmonary hypertension patients. Session : Late-breaking science in heart failure, cardiomyopathies, pulmonary ...

a first-in-class PD-1/IL-2 α-bias bispecific antibody fusion protein, as monotherapy for the treatment of unresectable locally advanced or metastatic mucosal or acral melanoma who have not ...

About IBI363 (First-in-class PD-1/IL-2α-bias bispecific antibody fusion protein) IBI363 is a first-in-class drug candidate independently developed by Innovent Biologics. It is a PD-1/IL-2 ...